Longevity Peptides: MOTS-c, Epithalon, and Mitochondrial Research

Last Updated: April 2026 | v1.0

The study of aging at the molecular level has entered a new era with the discovery of peptides encoded by the mitochondrial genome, the identification of telomerase-modulating sequences, and a growing appreciation for the role of cellular energy metabolism in organismal longevity. Longevity peptides — a broad category encompassing mitochondrial-derived peptides (MDPs), synthetic telomerase-targeting sequences, and mitochondria-targeted therapeutics — have become a significant area of preclinical and translational investigation. Researchers across disciplines are examining how these compounds influence fundamental processes such as mitochondrial bioenergetics, telomere maintenance, NAD+ metabolism, and cellular senescence. This pillar page provides a research-focused overview of MOTS-c, Epithalon, SS-31 (Elamipretide), and NAD+, summarizing the peer-reviewed literature, comparing mechanisms, and noting the limitations that define this early-stage but rapidly evolving field.

What Are Longevity Peptides and Why Are They Studied?

The term “longevity peptides” does not refer to a single pharmacological class but rather to a collection of peptides and related compounds that have been investigated in the context of aging biology. What unites them is their relevance to processes that are consistently implicated in aging: mitochondrial dysfunction, telomere shortening, NAD+ depletion, and the accumulation of senescent cells.

Mitochondria, long understood as the cell’s primary energy-producing organelles, are now recognized as signaling hubs that communicate with the nucleus through retrograde signaling pathways. The discovery of mitochondrial-derived peptides (MDPs) — small open reading frames encoded within the mitochondrial genome — has opened an entirely new dimension in aging research (PubMed: 31278058). These peptides, including humanin and MOTS-c, appear to function as signaling molecules that regulate metabolism, stress responses, and cellular homeostasis.

Telomere biology represents another major axis of longevity research. Telomeres — the protective caps at the ends of chromosomes — shorten with each cell division, and their attrition has been correlated with aging phenotypes across species. Compounds like Epithalon have been studied for their potential to influence telomerase, the enzyme responsible for telomere maintenance.

Mitochondria-targeted therapeutics such as SS-31 (Elamipretide) approach the problem from a bioenergetic angle, aiming to stabilize the inner mitochondrial membrane and restore electron transport chain (ETC) efficiency. Meanwhile, NAD+ — a coenzyme rather than a peptide — has gained attention because of its central role in sirtuin activation and its well-documented decline during aging.

Together, these compounds represent distinct but interconnected approaches to understanding the molecular mechanisms of aging. Importantly, the vast majority of longevity peptide research remains preclinical, conducted in cell culture systems and animal models. Researchers use these compounds as tools to probe fundamental biological questions rather than as established therapeutic agents.

What Is MOTS-c and How Does It Function as a Mitochondrial Peptide?

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a 16-amino-acid peptide discovered in 2015 by Changhan Lee and colleagues at the University of Southern California. It is encoded within the mitochondrial 12S rRNA gene, making it one of the first identified mitochondrial-derived peptides with systemic signaling functions (PubMed: 25738459).

Mechanism of Action

MOTS-c has been investigated primarily for its effects on metabolic regulation. In preclinical models, MOTS-c administration has been associated with activation of AMP-activated protein kinase (AMPK), a master regulator of cellular energy balance. AMPK activation triggers a cascade of downstream effects including enhanced glucose uptake, increased fatty acid oxidation, and inhibition of lipogenesis. The peptide appears to act by modulating the folate-methionine cycle, which in turn affects the cellular pool of 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), a known AMPK activator.

Exercise Mimetic Properties

One of the most widely cited aspects of MOTS-c research is its characterization as an “exercise mimetic.” In a 2016 study, researchers demonstrated that MOTS-c administration in mouse models produced metabolic effects that partially overlapped with those of physical exercise, including improved insulin sensitivity and resistance to diet-induced obesity (PubMed: 27165007). The peptide was also found to translocate to the nucleus in response to metabolic stress, where it regulates gene expression through interactions with antioxidant response elements (AREs).

MOTS-c in Aging Models

In aging-specific research, circulating MOTS-c levels have been observed to decline with age in both rodent models and human plasma samples. This age-associated decline has prompted investigation into whether exogenous MOTS-c administration might restore metabolic parameters in aged organisms. Preclinical studies in aged mice have reported improvements in physical performance, insulin sensitivity, and body composition following MOTS-c treatment, though these findings have not been replicated in human clinical trials.

What Is Epithalon and How Is It Studied in Telomerase Research?

Epithalon (also spelled Epitalon) is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly (AEDG). It was developed by Professor Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology and has been the subject of several decades of research, primarily within Russian biogerontology literature.

Telomerase Activation

The primary mechanism investigated in Epithalon research is its reported ability to activate telomerase, the ribonucleoprotein enzyme that adds TTAGGG repeats to the ends of chromosomes. In a key study published in 2003, Khavinson and colleagues reported that Epithalon treatment increased telomerase activity in human somatic cells in culture, extending the replicative lifespan of fetal fibroblasts beyond the Hayflick limit without inducing malignant transformation (PubMed: 12937225). The proposed mechanism involves upregulation of the catalytic subunit of telomerase (hTERT) gene expression.

Pineal Gland and Melatonin

A second line of Epithalon research focuses on the pineal gland and melatonin production. The pineal gland undergoes calcification and functional decline with age, resulting in reduced melatonin secretion — a process that has been linked to disrupted circadian rhythms and sleep architecture in aging. Khavinson’s group reported that Epithalon administration in aged rats was associated with restoration of evening melatonin peaks toward levels observed in younger animals (PubMed: 14501183). This pineal-regulatory effect is hypothesized to mediate at least some of the compound’s observed effects on aging parameters in animal studies.

Longevity Studies in Animal Models

Several studies from Khavinson’s laboratory have reported that Epithalon administration was associated with increased mean lifespan in rodent and Drosophila models. These studies observed effects on tumor incidence, immune function, and neuroendocrine parameters. However, as discussed in the limitations section below, these findings originate predominantly from a single research group, and independent replication by other laboratories remains limited.

What Is SS-31 (Elamipretide) and How Does It Target Mitochondria?

SS-31, also known as Elamipretide and marketed under the research name Bendavia, is a synthetic tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) developed by Hazel Szeto and Peter Bhatt-Schiller. It belongs to the Szeto-Schiller (SS) family of peptides, which are characterized by an alternating aromatic-cationic motif that enables selective accumulation in the inner mitochondrial membrane.

Mitochondrial Membrane Targeting

Unlike most mitochondria-targeted compounds that rely on membrane potential-driven accumulation, SS-31 concentrates in the inner mitochondrial membrane (IMM) through a mechanism that is at least partially independent of mitochondrial membrane potential. This is significant because dysfunctional mitochondria — precisely the ones that would benefit most from therapeutic intervention — often have reduced membrane potential. SS-31’s ability to accumulate in these compromised organelles makes it a particularly interesting research tool (PubMed: 26448851).

Cardiolipin Interaction

A key mechanistic insight came from the discovery that SS-31 interacts specifically with cardiolipin, a phospholipid found almost exclusively in the inner mitochondrial membrane. Cardiolipin plays a critical structural and functional role in organizing electron transport chain (ETC) complexes into supercomplexes, known as respirasomes. Age-associated changes in cardiolipin content and composition have been linked to declining mitochondrial efficiency. Research has demonstrated that SS-31 binds to cardiolipin and may stabilize the cristae structure of the IMM, thereby supporting efficient electron transfer and ATP production while reducing electron leak and reactive oxygen species (ROS) generation (PubMed: 24413180).

Preclinical and Clinical Research

SS-31 has been studied in a variety of preclinical models relevant to aging, including cardiac ischemia-reperfusion injury, skeletal muscle atrophy, renal dysfunction, and neurodegenerative disease models. In aged mouse models, SS-31 treatment has been associated with improved mitochondrial function, reduced oxidative damage, and restoration of proteostasis in cardiac and skeletal muscle tissue.

Notably, SS-31 (as Elamipretide) has advanced further toward clinical translation than most longevity peptides. Clinical trials have been conducted in the context of primary mitochondrial myopathy (the MMPOWER trials), heart failure with preserved ejection fraction (HFpEF), and Barth syndrome. While these trials are focused on specific disease indications rather than “anti-aging” per se, they provide valuable pharmacokinetic and safety data that inform the broader research landscape.

Peptideware provides SS-31 (10mg) for qualified laboratory research applications.

What Role Does NAD+ Play in Longevity Research?

NAD+ is a coenzyme found in all living cells, where it participates in hundreds of enzymatic reactions. It exists in oxidized (NAD+) and reduced (NADH) forms and serves as a critical electron carrier in the mitochondrial electron transport chain. Beyond its metabolic role, NAD+ functions as a substrate for several enzyme families with direct relevance to aging biology.

NAD+ and Sirtuins

Sirtuins (SIRT1-7 in mammals) are a family of NAD+-dependent deacylases and ADP-ribosyltransferases that regulate a broad range of cellular processes including DNA repair, gene silencing, mitochondrial biogenesis, inflammation, and stress resistance. Because sirtuins require NAD+ as a co-substrate (consuming it in each catalytic cycle), cellular sirtuin activity is directly linked to NAD+ availability. The well-documented decline in NAD+ levels during aging has been hypothesized to contribute to reduced sirtuin activity, creating a cascade of downstream effects on genomic stability, mitochondrial function, and inflammatory signaling (PubMed: 29634461).

NAD+ Decline During Aging

Multiple studies in rodent models have documented a progressive decline in tissue NAD+ levels with age, with reductions observed in liver, skeletal muscle, brain, and adipose tissue. The mechanisms underlying this decline are multifactorial and include increased activity of NAD+-consuming enzymes (particularly CD38 and PARP1), reduced expression of NAD+ biosynthetic enzymes (particularly NAMPT in the salvage pathway), and chronic low-grade inflammation that drives NAD+ consumption.

NAD+ Precursors and Supplementation Research

Much of the current research focus involves strategies to restore NAD+ levels, either through direct supplementation or through NAD+ precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). In preclinical models, NAD+ repletion has been associated with improvements in mitochondrial function, stem cell function, DNA repair capacity, and various age-related phenotypes. However, the bioavailability and optimal delivery route for NAD+ itself remain subjects of active investigation, as direct NAD+ supplementation faces challenges related to molecular size and cellular uptake mechanisms.

NAD+ and Mitochondrial Function

The connection between NAD+ and mitochondrial function is bidirectional. NAD+ is required for the ETC to function properly (as NADH donates electrons at Complex I), and mitochondrial dysfunction can in turn impair NAD+ regeneration. This creates a potential vicious cycle in aging tissues where declining NAD+ leads to mitochondrial dysfunction, which further depletes NAD+. This intersection with mitochondrial biology is precisely why NAD+ research complements the study of mitochondrial-derived peptides like MOTS-c and mitochondria-targeted peptides like SS-31.

How Do Longevity Research Compounds Compare?

The following table summarizes the key characteristics of the primary longevity research compounds discussed in this overview. Each compound approaches aging biology from a distinct mechanistic angle, and researchers often study them in complementary rather than competitive contexts.

Compound	Type	Primary Target	Molecular Weight	Key Study	Peptideware Product
MOTS-c	Mitochondrial-derived peptide (16 aa)	AMPK pathway / folate-methionine cycle	~2,174 Da	Lee et al. 2015	MOTS-c with DAC
Epithalon	Synthetic tetrapeptide (Ala-Glu-Asp-Gly)	Telomerase (hTERT) / pineal gland	~390 Da	Khavinson 2003	Coming Soon
SS-31 (Elamipretide)	Synthetic mitochondria-targeted peptide	Inner mitochondrial membrane / cardiolipin	~640 Da	Szeto 2014	SS-31 (10mg)
NAD+	Coenzyme (not a peptide)	Sirtuins / ETC Complex I / PARPs	~663 Da	Rajman et al. 2018	NAD+ (500mg)

Crossover compounds of interest: Researchers studying longevity pathways also frequently investigate GHK-Cu, a copper-binding tripeptide studied for its effects on gene expression and tissue remodeling (see our GHK-Cu Research Guide), and ARA-290, an erythropoietin-derived peptide investigated in neuroprotection research that intersects with aging neurobiology.

How Are Longevity Peptides Reconstituted for Laboratory Research?

Proper reconstitution is essential for maintaining peptide stability and ensuring reproducible results in longevity research. The following general principles apply to most research peptides in this category, though researchers should always consult product-specific documentation and relevant literature for optimized protocols.

General Reconstitution Protocol

1. Solvent Selection: Most longevity peptides, including MOTS-c and SS-31, are water-soluble and can be reconstituted in sterile bacteriostatic water (0.9% benzyl alcohol) for research use. NAD+ is also water-soluble. Epithalon may require a slightly acidic aqueous solution for optimal solubility.
2. Technique: Direct the solvent stream against the vial wall rather than directly onto the lyophilized peptide cake. Allow the peptide to dissolve gradually — do not vortex aggressively, as this can cause aggregation and denaturation.
3. Storage: Reconstituted peptide solutions should be stored at 2-8°C for short-term use (typically up to 2-4 weeks) or aliquoted and stored at -20°C for longer-term storage. Avoid repeated freeze-thaw cycles.
4. Concentration Calculation: Use the peptide reconstitution calculator to determine the appropriate volume of solvent for your desired working concentration.

For a comprehensive step-by-step guide covering all peptide types, see our Peptide Reconstitution 101 guide. All Peptideware products are accompanied by third-party certificates of analysis — view our Lab Results page for current documentation.

What Are the Current Limitations of Longevity Peptide Research?

While the preclinical literature on longevity peptides is promising, researchers and observers should maintain appropriate scientific skepticism. Several significant limitations characterize this field.

Predominance of Animal Models

The vast majority of longevity peptide research has been conducted in cell culture systems and rodent models. While these models provide valuable mechanistic insights, the translation of aging-related findings from mice to humans has historically been challenging. Lifespan extension in short-lived model organisms does not reliably predict effects in humans, and many interventions that extended rodent lifespan have failed to demonstrate similar effects in longer-lived species.

Limited Independent Replication

This concern is particularly relevant for Epithalon research. The majority of published studies on Epithalon’s effects on telomerase activity, pineal gland function, and lifespan originate from Professor Khavinson’s laboratory and affiliated institutions. While this body of work is substantial, the relative scarcity of independent replication by unaffiliated research groups is a notable gap. Independent validation is a cornerstone of scientific confidence, and the longevity peptide field would benefit from broader replication efforts.

NAD+ Bioavailability Questions

The optimal route and form for NAD+ repletion remain debated. Direct NAD+ supplementation faces challenges related to the molecule’s size, charge, and susceptibility to degradation. While NAD+ precursors (NR, NMN) have shown promise in raising tissue NAD+ levels, questions persist about whether the magnitude of increase is sufficient to produce meaningful biological effects, particularly in specific tissue compartments such as the mitochondrial matrix.

Dosing and Pharmacokinetic Gaps

For most longevity peptides, detailed pharmacokinetic data in large mammals (including humans) are limited or absent. Half-life, tissue distribution, blood-brain barrier penetration, and dose-response relationships remain incompletely characterized for compounds like MOTS-c and Epithalon. SS-31 is an exception, as its advancement into clinical trials has generated more comprehensive pharmacokinetic data.

Complexity of Aging Biology

Aging is a multifactorial process involving dozens of interconnected pathways. No single peptide or compound is likely to address all hallmarks of aging simultaneously. The most scientifically rigorous approach recognizes that these compounds are research tools for understanding specific aspects of aging biology, not comprehensive solutions. The field is still working to understand how different aging pathways interact and whether targeting one pathway produces compensatory changes in others.

Publication Bias

As with many biomedical research fields, there is a risk of publication bias — the tendency for positive results to be published more frequently than null or negative findings. Researchers should consider this when evaluating the overall evidence base for any longevity compound, as well as when consulting resources like our research overviews, which aim to present balanced assessments of available data.

Frequently Asked Questions

What are mitochondrial-derived peptides (MDPs)?

Mitochondrial-derived peptides are small peptides encoded by short open reading frames within the mitochondrial genome. Unlike the 13 well-characterized proteins encoded by mitochondrial DNA, MDPs were discovered more recently and appear to function as signaling molecules rather than structural components of the electron transport chain. The three best-characterized MDPs are humanin, MOTS-c, and SHLP1-6 (Small Humanin-Like Peptides). These peptides have been investigated for roles in metabolic regulation, stress response, and cell survival signaling (PubMed: 31278058).

How does MOTS-c differ from other exercise mimetics studied in research?

MOTS-c is unique among investigated exercise mimetics in that it is an endogenous peptide — naturally produced by the mitochondrial genome — rather than a synthetic pharmaceutical compound. Its mechanism involves AMPK activation through modulation of the folate-methionine cycle, which is distinct from other exercise mimetics like AICAR (a direct AMPK activator) or GW501516 (a PPARdelta agonist). Preclinical research has suggested that MOTS-c levels may increase transiently during exercise and decline with age (PubMed: 27165007).

What is the relationship between telomerase activation and longevity research?

Telomerase is the enzyme that extends telomeres, the protective DNA-protein structures at chromosome ends. In most human somatic cells, telomerase is expressed at very low levels, leading to progressive telomere shortening with each cell division. When telomeres become critically short, cells enter senescence or undergo apoptosis. Research into telomerase activators like Epithalon is motivated by the hypothesis that maintaining telomere length could delay cellular senescence. However, telomerase activation must be studied carefully, as it is also a hallmark of most cancer cells, which use telomerase to achieve replicative immortality (PubMed: 12937225).

Why is cardiolipin important in mitochondrial aging research?

Cardiolipin is a unique phospholipid found almost exclusively in the inner mitochondrial membrane, where it constitutes approximately 20% of total lipid content. It plays essential roles in organizing ETC complexes into supercomplexes (respirasomes), maintaining cristae curvature, and supporting the function of multiple mitochondrial carrier proteins. Research has shown that cardiolipin content and composition change with age — particularly an increase in oxidized cardiolipin species and a decrease in the predominant tetralinoleoyl species. SS-31 is studied in this context because of its specific interaction with cardiolipin (PubMed: 24413180).

Can NAD+ be directly supplemented, or are precursors required?

This is an active area of investigation. NAD+ is a relatively large, charged molecule (MW ~663 Da), and its ability to cross cell membranes directly has been debated. Some research suggests that extracellular NAD+ may be cleaved by ectoenzymes (such as CD73) to generate nicotinamide riboside (NR) or nicotinamide, which can then enter cells and be used to resynthesize intracellular NAD+. NAD+ precursors like NR and NMN have been more extensively studied for oral bioavailability. Peptideware offers NAD+ (500mg) for laboratory research investigating these questions (PubMed: 29634461).

What is the difference between SS-31 and other mitochondria-targeted antioxidants?

Most mitochondria-targeted antioxidants, such as MitoQ and SkQ1, use a triphenylphosphonium (TPP+) cation to drive accumulation into mitochondria based on membrane potential. SS-31 uses a different targeting strategy — its alternating aromatic-cationic structure enables concentration in the inner mitochondrial membrane through a mechanism that is at least partially independent of membrane potential. This distinction is important because dysfunctional mitochondria with reduced membrane potential — precisely those most relevant to aging research — may not accumulate TPP+-based compounds effectively, whereas SS-31 accumulation appears to be maintained (PubMed: 26448851).

Are longevity peptides approved for human use?

As of April 2026, none of the longevity peptides discussed in this overview — MOTS-c, Epithalon, or SS-31 — are approved by the FDA for the prevention or treatment of aging or any age-related condition. SS-31 (Elamipretide) has been investigated in clinical trials for specific mitochondrial diseases and cardiac conditions, but has not received FDA approval for longevity indications. NAD+ and its precursors are available as dietary supplements in some formulations but are not approved drugs. All compounds discussed here are provided by Peptideware for research use only.